Developing a high fibre carbonated soft drink with improved digestive tolerance and beneficial impacts on the gut microbiome: FUNKi-2.0

我们的愿景是开发一种新型的碳酸软饮料，强化纤维混合物，对肠道微生物有益，为英国人提供一种美味、方便和负担得起的方式，让他们轻松实现每天30克的推荐纤维摄入量。Quadram研究所（QI）使用先进的体外结肠发酵模型对目前的碳酸饮料配方（FUNKi-1.0）对肠道微生物群的初步评估将确定一种最佳的纤维混合物用于重新配方。该项目将使FUNKi推出英国第一款含有纤维混合物的碳酸软饮料（FUNKi-2.0），该饮料已被证明具有消化耐受性，对肠道微生物有益，并有可能改善人体健康。多吃纤维可以降低患心脏病、中风、2型糖尿病和肠癌的风险（NHS）。尽管如此，只有9%的英国人达到了建议的每天30克的纤维摄入量！(FDF)。英国对csd的需求正在增长，年消费量将从2021年的46亿升增加到2026年的49亿升。为CSDs提供最佳纤维摄入量的概念是强大的；如果只有1%的英国人每天吃一罐FUNKi-2.0，这将意味着670多万人将达到他们的膳食纤维摄入量，降低心血管疾病和肥胖的风险——有助于抵消NHS在饮食相关慢性疾病上的9%的支出，以及到2050年因肥胖而产生的估计499亿英镑的更广泛的社会成本。

Our vision is to develop a novel carbonated soft drink fortified with a fibre-blend with evidence-based benefits to gut microbes that offers a tasty, convenient and affordable way for the UK to easily achieve their recommended fibre intake of 30g each day.An initial assessment of the current carbonated drink formulation (FUNKi-1.0) on the gut microbiome using advanced _in vitro_ colonic fermentation models at Quadram Institute (QI) will identify an optimal fibre-blend for reformulation. This project will enable FUNKi to launch the UK's first carbonated soft drink fortified with a fibre-blend (FUNKi-2.0) that has proven digestive tolerance, benefits to gut microbes and potential to improve human health.FUNKi-2.0 will enable consumers to increase their fibre intake in a novel and innovative way that is convenient. Eating plenty of fibre is associated with lower risks of heart disease, stroke, type 2 diabetes and bowel cancer (NHS). Despite this, only 9% of the UK population achieve the recommended fibre intake of 30g per day! (FDF). The UK's appetite for CSDs is growing with annual consumption rising from 4.6 billion litres in 2021 to an estimated 4.9 billion litres in 2026\. This concept of providing optimal fibre intake in CSDs is powerful; if only 1% of the UK had one can of FUNKi-2.0 each day, that would mean 6.7 million more people would achieve their dietary fibre intake and reduce their risk of cardiovascular disease and obesity - helping to offset the 9% of all NHS spend on diet-related chronic disease and the estimated £49.9 billion wider societal costs predicted to arise from obesity by 2050\.